Adocia SA (ADOC.PA)
EUR 6.39
(1.59%)
EUR 6.39
(1.59%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 272 Thousand EUR | 98.54% |
| 2022 | 137 Thousand EUR | -73.5% |
| 2021 | 517 Thousand EUR | -9.14% |
| 2020 | 569 Thousand EUR | 214.36% |
| 2019 | 181 Thousand EUR | 38.17% |
| 2018 | 131 Thousand EUR | 32.32% |
| 2017 | 99 Thousand EUR | 50.0% |
| 2016 | 66 Thousand EUR | 186.96% |
| 2015 | 23 Thousand EUR | -34.29% |
| 2014 | 35 Thousand EUR | -71.77% |
| 2013 | 124 Thousand EUR | 20.39% |
| 2012 | 103 Thousand EUR | 10.75% |
| 2011 | 93 Thousand EUR | -16.96% |
| 2010 | 112 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 600 Thousand EUR | 0.0% |
| 2023 Q3 | 132 Thousand EUR | 9.09% |
| 2023 Q4 | 272 Thousand EUR | 106.06% |
| 2023 Q1 | 121 Thousand EUR | -11.68% |
| 2023 FY | 272 Thousand EUR | 98.54% |
| 2023 Q2 | 121 Thousand EUR | 0.0% |
| 2022 FY | 137 Thousand EUR | -73.5% |
| 2022 Q3 | 137 Thousand EUR | -6.16% |
| 2022 Q4 | 137 Thousand EUR | 0.0% |
| 2022 Q2 | 146 Thousand EUR | 0.0% |
| 2022 Q1 | 146 Thousand EUR | -71.76% |
| 2021 Q3 | 517 Thousand EUR | 5.94% |
| 2021 Q4 | 517 Thousand EUR | 0.0% |
| 2021 Q1 | 488 Thousand EUR | -14.24% |
| 2021 FY | 517 Thousand EUR | -9.14% |
| 2021 Q2 | 488 Thousand EUR | 0.0% |
| 2020 Q2 | 150 Thousand EUR | 0.0% |
| 2020 Q1 | 150 Thousand EUR | -17.13% |
| 2020 Q3 | 569 Thousand EUR | 279.33% |
| 2020 Q4 | 569 Thousand EUR | 0.0% |
| 2020 FY | 569 Thousand EUR | 214.36% |
| 2019 Q2 | 94 Thousand EUR | 0.0% |
| 2019 Q4 | 181 Thousand EUR | 0.0% |
| 2019 FY | 181 Thousand EUR | 38.17% |
| 2019 Q1 | 94 Thousand EUR | -28.24% |
| 2019 Q3 | 181 Thousand EUR | 92.55% |
| 2018 Q3 | 131 Thousand EUR | 61.73% |
| 2018 FY | 131 Thousand EUR | 32.32% |
| 2018 Q4 | 131 Thousand EUR | 0.0% |
| 2018 Q2 | 81 Thousand EUR | 0.0% |
| 2018 Q1 | 81 Thousand EUR | -18.18% |
| 2017 Q1 | 103 Thousand EUR | 56.06% |
| 2017 Q2 | 103 Thousand EUR | 0.0% |
| 2017 Q3 | 99 Thousand EUR | -3.88% |
| 2017 Q4 | 99 Thousand EUR | 0.0% |
| 2017 FY | 99 Thousand EUR | 50.0% |
| 2016 Q2 | 49 Thousand EUR | 0.0% |
| 2016 FY | 66 Thousand EUR | 186.96% |
| 2016 Q1 | 49 Thousand EUR | 113.04% |
| 2016 Q3 | 66 Thousand EUR | 34.69% |
| 2016 Q4 | 66 Thousand EUR | 0.0% |
| 2015 Q3 | 23 Thousand EUR | 0.0% |
| 2015 Q2 | 23 Thousand EUR | 0.0% |
| 2015 FY | 23 Thousand EUR | -34.29% |
| 2015 Q1 | 23 Thousand EUR | -34.29% |
| 2015 Q4 | 23 Thousand EUR | 0.0% |
| 2014 Q2 | 109 Thousand EUR | 0.0% |
| 2014 Q3 | 35 Thousand EUR | -67.89% |
| 2014 Q4 | 35 Thousand EUR | 0.0% |
| 2014 Q1 | 109 Thousand EUR | -12.1% |
| 2014 FY | 35 Thousand EUR | -71.77% |
| 2013 Q1 | 118 Thousand EUR | 14.56% |
| 2013 Q4 | 124 Thousand EUR | 0.0% |
| 2013 Q2 | 118 Thousand EUR | 0.0% |
| 2013 Q3 | 124 Thousand EUR | 5.08% |
| 2013 FY | 124 Thousand EUR | 20.39% |
| 2012 Q3 | 103 Thousand EUR | 15.73% |
| 2012 Q4 | 103 Thousand EUR | 0.0% |
| 2012 FY | 103 Thousand EUR | 10.75% |
| 2012 Q2 | 89 Thousand EUR | 0.0% |
| 2011 FY | 93 Thousand EUR | -16.96% |
| 2011 Q4 | 93 Thousand EUR | 0.0% |
| 2010 FY | 112 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -23.077% |
| ABIVAX Société Anonyme | 1.00 EUR | -27199900.0% |
| Aelis Farma SA | 53 Thousand EUR | -413.208% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 84.377% |
| genOway Société anonyme | 982.75 Thousand EUR | 72.323% |
| IntegraGen SA | 311.44 Thousand EUR | 12.666% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -65.227% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 124.534% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 77.788% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 328.234% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -198.901% |
| Valbiotis SA | 1 Million EUR | 72.935% |
| TheraVet SA | 123.34 Thousand EUR | -120.525% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -27199900.0% |
| argenx SE | 281.12 Million EUR | 99.903% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | 78.413% |
| DBV Technologies S.A. | 1.00 USD | -27199900.0% |
| Galapagos NV | 73.97 Million EUR | 99.632% |
| Genfit S.A. | 4000.00 EUR | -6700.0% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -27199900.0% |
| Innate Pharma S.A. | 1.00 EUR | -27199900.0% |
| Inventiva S.A. | 417 Thousand EUR | 34.772% |
| MaaT Pharma SA | 190 Thousand EUR | -43.158% |
| MedinCell S.A. | -6.71 Million EUR | 104.051% |
| Nanobiotix S.A. | 200 Thousand EUR | -36.0% |
| Onward Medical N.V. | 936 Thousand EUR | 70.94% |
| Oryzon Genomics S.A. | 6029.00 EUR | -4411.528% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -112.5% |
| Pharming Group N.V. | 51.38 Million EUR | 99.471% |
| Poxel S.A. | 2.95 Million EUR | 90.798% |
| GenSight Biologics S.A. | 1.00 EUR | -27199900.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.974% |
| Valneva SE | 44.46 Million EUR | 99.388% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -27199900.0% |